Brickell Biotech up big on positive data on lead drug
positive data from a Japan-based Phase 3 clinical trial evaluating lead candidate topical sofpironium bromide gel, 5% in patients with primary axillary hyperhidrosis (excessive sweating on the hands, feet and underarms).
53.9% of treated patients achieved at least a 50% reduction in gravimetric sweat production and improved to a score of 1 or 2 in a scale called HDSS at the end of treatment, compared to 36.4% for vehicle
Kaken has filed a marketing application in Japan. It also has development and commercialization rights in Korea, China and certain other countries in Asia.
seekingalpha.com/news/3582884-brickell-biotech-up-big-on-positive-data-on-lead-drug
53.9% of treated patients achieved at least a 50% reduction in gravimetric sweat production and improved to a score of 1 or 2 in a scale called HDSS at the end of treatment, compared to 36.4% for vehicle
Kaken has filed a marketing application in Japan. It also has development and commercialization rights in Korea, China and certain other countries in Asia.
seekingalpha.com/news/3582884-brickell-biotech-up-big-on-positive-data-on-lead-drug
Wyłączenie odpowiedzialności
Informacje i publikacje przygotowane przez TradingView lub jego użytkowników, prezentowane na tej stronie, nie stanowią rekomendacji ani porad handlowych, inwestycyjnych i finansowych i nie powinny być w ten sposób traktowane ani wykorzystywane. Więcej informacji na ten temat znajdziesz w naszym Regulaminie.